Appointments:
Associate Scientific Director, Institute of Infection and Immunity, Canadian Institutes for Health Research (CIHR)
Adjunct Assistant Professor, Microbiology and Immunology, Dalhousie
Affiliations:
Member, Vaccine Discovery Group, CCfV
Research Interests:
Dr. Marianne Stanford has expertise in preclinical research activities and clinical immunology assessment of cancer immunotherapies and infectious disease vaccines. She also serves as adjunct professor in Microbiology and Immunology at Dalhousie University, as a member of the Vaccine Discovery group of the Canadian Centre for Vaccinology, and as an Associate Member of the Beatrice Hunter Cancer Research Institute. Marianne conducted her postdoctoral training at the Robarts Research Institute and at the Ottawa Hospital Research Institute (OHRI), focusing her research on the use of viruses in the development of novel cancer treatments. While at the OHRI, she worked with Jennerex Biotherapeutics (now SillaJen) in the development of Pexa-Vec for human clinical trials. She received her BSc and MSc from Memorial University of Newfoundland and her PhD from Dalhousie University. In her spare time, Marianne is involved in science outreach and policy and is the former Chair of the Canadian Association of Postdoctoral Scholars.
Involvement with BHCRI to date:
Dr. Stanford is an Associate Member. She is a member of the Research Committee, has served on and chaired numerous Scientific Review Panels.
Phone:
(902) 440-4674
Email:
Publications:
Brewer KD, Weir GM, Dude I, Davis C, Parsons C, Penwell A, Rajagopalan R, Sammatur L, Bowen CV, Stanford MM. Unique depot formed by an oil based vaccine facilitates active antigen uptake and provides effective tumour control. J Biomed Sci. 2018 Jan 27;25(1):7. doi: 10.1186/s12929-018-0413-9.
Tremblay ML, Davis C, Bowen CV, Stanley O, Parsons C, Weir G, Karkada M, Stanford MM, Brewer KD. Using MRI cell tracking to monitor immune cell recruitment in response to a peptide-based cancer vaccine. Magn Reson Med. 2017 Nov 29. doi: 10.1002/mrm.27018.
Weir GM,, Karkada M, Hoskin D, Stanford MM, MacDonald L, Mansour M, Liwski RS .Combination of poly I:C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo. PLOS one 2017 12(6) e0180073.
Weir GM, Hrystenko O, Quinton T, Berinstein NL, Stanford MM, Mansour M. Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. Journal for ImmunoTherapy of Cancer 18(4):68 2016
Brewer KD, DeBay DR, Dude I, Davis C, Lake K, Parsons C, Rajagopalan R, Weir G, Stanford MM, Mansour M, Bowen CV. Using lymph node swelling as a potential biomarker for successful vaccination. Oncotarget 2016 May 24. doi: 10.18632/oncotarget.9580. [Epub ahead of print].
DeBay DR, Brewer KD, LeBlanc SA, Weir GM, Stanford MM, Mansour M, Bowen CV. Using MRI to evaluate and predict therapeutic success from depot-based cancer vaccines. Molecular Therapy Methods Clinical Development. 2015 Dec 16;2:15048. doi: 10.1038/mtm.2015.48. eCollection 2015.
Berinstein NL, Karkada M, Oza AM, Odunsi K,Villella JA,Nemunaitis JJ, Morse MA, Pejovic T, Bentley J, Buyse M, Nigam R, Weir GM, MacDonald LD, Quinton T, Rajagopalan R, Sharp K, Penwell A, Sammatur L, Burzykowski T, Stanford MM, Mansour M. Survivin targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncoimmunology. 2015. 2015 May 7;4(8):e1026529. eCollection 2015 Aug